Philogen SpA (MIL:PHIL) Issuance of Debt : €0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Philogen SpA Issuance of Debt?

Philogen SpA's Issuance of Debt for the six months ended in Dec. 2024 was €0.00 Mil.

Philogen SpA's Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil.

Philogen SpA Issuance of Debt Historical Data

The historical data trend for Philogen SpA's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Philogen SpA Issuance of Debt Chart

Philogen SpA Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Issuance of Debt

5.01

Philogen SpA Semi-Annual Data
	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Issuance of Debt	Get a 7-Day Free Trial					-	-	-	-	-

Philogen SpA Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Philogen SpA Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Philogen SpA's Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Philogen SpA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Philogen SpA (MIL:PHIL) » Definitions » Issuance of Debt

Comparable Companies

Traded in Other Exchanges

78Q:Germany

Address

Piazza La Lizza No. 7, Siena, ITA, 53100

Website

https://www.philogen.com

Philogen SpA is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. The company's focus is predominantly related to oncology drug development, although the company has also brought products for the treatment of chronic inflammatory diseases to the clinic. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others. Geographically, the company operates in the European Union, Switzerland, and the United States of America.